REG - Celadon Pharma. PLC - Notice of Results and Investor Presentation

Celadon PharmaceuticalsAnnouncement

18/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230918:nRSR7427Ma&default-theme=true

RNS Number : 7427M  Celadon Pharmaceuticals PLC  18 September 2023

 

Celadon Pharmaceuticals Plc

 

("Celadon" or the "Company")

 

Notice of Results and Investor Presentation

 

LONDON, 18 September 2023: Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based
pharmaceutical company focused on the development, production and sale of
breakthrough cannabis-based medicines, will announce its results for the six
months ended 30 June 2023 on Thursday 28 September 2023.

 

Analyst Briefing: 10.00am BST, Thursday 28 September 2023

 

Management will host a virtual analyst presentation followed by a Q&A
session at 10.00am BST on Thursday 28 September 2023. Analysts wishing to join
should register their interest by contacting celadon@powerscourt-group.com
(mailto:celadon@powerscourt-group.com) .

 

Investor Presentation: 3.30pm BST, Thursday 28 September 2023

 

Management will be hosting a live presentation and Q&A session via the
online platform, Investor Meet Company, at 3.30pm BST on Thursday 28 September
2023.

 

The presentation is open to analysts and all existing and potential
shareholders. Questions can be submitted pre-event via the Investor Meet
Company dashboard or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free via:
https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor
(https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor)

 

Investors who already follow Celadon on the Investor Meet Company platform
will automatically receive an invitation to the event.

 

Enquiries:

 

 Celadon Pharmaceuticals Plc
 James Short, CEO                                          Via Powerscourt

 Arthur Wakeley, MD

 Jonathan Turner, CFO

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Bobbie Hilliam / Max Hartley                              +44 (0)20 7523 8000

 Powerscourt Group
 Sarah MacLeod / Nick Johnson / Sam Austrums               +44 (0)20 7250 1446

                                                           celadon@powerscourt-group.com

 

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on
the research, cultivation, manufacturing, and sale of breakthrough
cannabis-based medicines. Its primary focus is on improving quality of life
for chronic pain sufferers, as well as exploring the potential of
cannabis-based medicines for other conditions such as autism. Its 100,000 sq.
ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation,
proprietary GMP extraction and manufacturing and an analytical and R&D
laboratory. Celadon's Home Office licence allows for the commercial supply of
its GMP pharmaceutical cannabis product. The Group owns an approved clinical
trial using cannabis based medicinal products to treat chronic pain in the UK.
Celadon also has a minority interest in early-stage biopharma Kingdom
Therapeutics which is developing a licensed cannabinoid medicine to treat
children with Autism Spectrum Disorder.

 

For further information please visit our website www.celadonpharma.co.uk
(http://www.celadonpharma.co.uk)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORNKFBBPBKKACD